Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NR082 Gene Therapy for LHON Associated With ND4 Mutation
NCT05293626Phase 2Active, not recruiting
- Sponsor
- Neurophth
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of esonadogene mvoparvovec in Leber hereditary optic neuropathy (LHON), sponsored by Neurophth. Primary endpoints: Incidence of adverse events (AEs) at 52 weeks, Incidence of serious adverse events (SAEs) at 52 weeks and 1 more. Started May 2023; status: active, not recruiting.
02
Drugs
esonadogene mvoparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT05293626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293626.